InVivoSIM anti-human IL-1β (Gevokizumab Biosimilar)

About InVivoSIM anti-human IL-1β (Gevokizumab Biosimilar)

This biosimilar antibody uses the same variable regions as the therapeutic antibody Gevokizumab, making it ideal for research use. Gevokizumab is a fully humanized monoclonal antibody that reacts with human IL-1β, a potent pro-inflammatory cytokine produced primarily by monocytes. Inflammatory signals, such as LPS, stimulate the synthesis and promote the accumulation of cytosolic stores of pro-IL1 β, and after inflammasome assembly-mediated CASP1 activation, pro-IL1 is processed to generate active cytokine for secretion. IL-1β is an important mediator of the inflammatory response and is involved in a variety of cellular activities, including cell proliferation, differentiation, apoptosis, and T and B lymphocyte activation, neutrophil influx and activation, cytokine production, antibody production, fibroblast proliferation, and the synthesis of collagen as well as prostaglandins. IL-1β promotes Th17 differentiation of T-cells and also shows synergism with IL-12 to induce IFN-γ synthesis from Th1 cells. The Gevokizumab antibody binds a unique IL-1β epitope that is proximal to, but does not overlap with, the receptor/ligand interface, and this interaction reduces the binding of IL-1 to its receptor, i.e., IL-1 receptor type I (IL-1RI or CD121a). Gevokizumab neutralizes the human IL-1β by binding to it, and this antibody is used in preclinical research involving in vitro and in vivo experimental models of type 1 diabetes mellitus, inflammation, rheumatoid arthritis, cardiovascular biology, and cancer immunotherapy.